We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
greenovation Biotech Strengthens Corporate Management
News

greenovation Biotech Strengthens Corporate Management

greenovation Biotech Strengthens Corporate Management
News

greenovation Biotech Strengthens Corporate Management

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "greenovation Biotech Strengthens Corporate Management"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

greenovation Biotech GmbH welcomes Andreas Hartmann, Ph.D. as the new Chief Business Officer. Prior to joining greenovation Dr. Hartmann established and managed the German operations for Therabel and Emergent BioSolutions and held local as well as international management, business development and marketing & sales positions at Emergent BioSolutions, Bavarian Nordic, Ares Serono, Sanofi-Winthrop and Janssen-Cilag.

With greenovation having passed the strategic turning point from an expression platform developer and service provider towards developing customized protein biopharmaceuticals, Dr. Hartmann will intensify the company's international efforts in establishing developmental collaborations and out-licensing/partnering of its advanced lead candidates and selected programs.

greenovation's proprietary Physcomitrella-based BryoTechnology™-platform is suitable for expressing complex multi-purpose proteins. In line with streamlining the business focus the BryoTechnology™-platform has now preferentially been dedicated to development and production of demanding proteins for pharmaceutical use.

The company's lead candidates, targeting unmet medical needs in orphan indications, are spearheaded by recombinant moss Alpha-Galactosidase, to be developed as enzyme-replacement Therapy (ERT) for patients with Fabry Disease. The pre-clinical development of moss Alpha-Galactosidase is close to being completed. With GMP-manufacturing and protein analytics having been fully established greenovation is confident to move this first ever moss-expressed biopharmaceutical candidate into clinical development in autumn 2014.

“We are pleased to welcome Dr. Hartmann to join greenovation's management team. His appointment underlines the company's recent clear cut specialization in biopharmaceuticals. Dr. Hartmann's extensive executive and hands-on operational knowledge and experience in international (bio)pharmaceutical industry makes him ideally qualified to help further developing and achieving greenovation's business goals and future progress", said Günter Steffen, Chairman of greenovation's Advisory Board.

Advertisement